secwatch / observer

8-K filed February 12, 2026, 6:59 PM ET ticker BNTC CIK 0001808898

earnings confidence high sentiment neutral materiality 0.70

Benitec Q2 FY2026 net loss $11.8M; all Cohort 1 patients respond to BB-301 at 12 months

Benitec Biopharma Inc.

2026-Q2 EPS reported -$0.48

Net loss of $11.8M ($0.26 per share) vs $9.6M YoY; total expenses $13.4M (up from $10.8M).
All 4 Cohort 1 completers in BB-301 Phase 1b/2a met Responder criteria at 12-month follow-up.
Patient 1 showed deepening improvements in swallow function and dysphagia at 24 months.
Cash and equivalents $189M; FDA meeting mid-2026 to confirm pivotal study design for BB-301.
Cohort 2 interim results expected mid-2026; first patient dosed in Q4 2025.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-047742
form_type: 8-K
ticker: BNTC
cik: 0001808898
company_name: Benitec Biopharma Inc.
filed_at: 2026-02-12T23:59:59+00:00
discovered_at: 2026-05-14T18:02:36.255384+00:00
generated_at: 2026-05-16T03:05:44.208754+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-047742
json_url: https://secwatch.observer/filing/0001193125-26-047742.json
markdown_url: https://secwatch.observer/filing/0001193125-26-047742.md
text_url: https://secwatch.observer/filing/0001193125-26-047742.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1808898/000119312526047742/0001193125-26-047742-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1808898/000119312526047742/bntc-20260212.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

GMRS

GMR Solutions Q1 revenue $1.46B (+6.6% YoY), net income $106M (+180% YoY), guides FY26 rev $5.9-6.2B

GMR Solutions Inc. June 1, 2026, 4:45 PM ET earnings Items 2.02, 9.01

same SEC item: 2.02, 9.01 same event type: earnings similar materiality

Filing page SEC filing

DAVEY TREE EXPERT CO

Davey Tree Q1 net loss widens to $10.7M; revenue flat at $435.8M

DAVEY TREE EXPERT CO June 1, 2026, 1:50 PM ET earnings Items 2.02, 9.01

same SEC item: 2.02, 9.01 same event type: earnings similar materiality

Filing page SEC filing

RMCF

Rocky Mountain Chocolate Factory Q4 revenue down 24% to $6.8M; net loss per share widens to $0.38

Rocky Mountain Chocolate Factory, Inc. June 1, 2026, 9:15 AM ET earnings Items 2.02, 9.01

same SEC item: 2.02, 9.01 same event type: earnings similar materiality

Filing page SEC filing

FNGR

FingerMotion FY2026 revenue down 32% to $24.1M; net loss widens to $7.0M

FingerMotion, Inc. May 29, 2026, 5:12 PM ET earnings Items 2.02, 7.01, 9.01

same SEC item: 2.02, 9.01 same event type: earnings similar materiality

Filing page SEC filing

BKE

Buckle Q1 net income $46.9M ($0.93/share), sales up 6.1% to $288.7M

BUCKLE INC May 29, 2026, 3:38 PM ET earnings Items 2.02, 9.01

same SEC item: 2.02, 9.01 same event type: earnings similar materiality

Filing page SEC filing

HIND

Vyome Q1 net loss $963K, cash $8.8M, inks JAK inhibitor licensing deal with Impetis

Vyome Holdings, Inc May 29, 2026, 8:42 AM ET earnings Items 2.02, 9.01

same SEC item: 2.02, 9.01 same event type: earnings similar materiality

Filing page SEC filing

ELMT

Elmet Group Q1 revenue up 21% to $56M; adjusted EBITDA +106% to $9.2M; record backlog $113M

Elmet Group Co. May 29, 2026, 8:05 AM ET earnings Items 2.02, 9.01

same SEC item: 2.02, 9.01 same event type: earnings similar materiality

Filing page SEC filing

GCO

Genesco reports Q1 sales beat, raises FY2027 EPS outlook; launches $40-50M cost program

GENESCO INC May 29, 2026, 7:07 AM ET earnings Items 2.02, 9.01

same SEC item: 2.02, 9.01 same event type: earnings similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-26-047742

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.